← Back to search
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
SAN ANTONIO, TX, 78229
Unclaimed
Prime contracting experience
15 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Veterans Affairs Department of Veterans Affairs | ANIMAL CARE & HANDLING SERVICES | — | $617,073 | Sep 4, 2026 | Apr 1, 2022 – Mar 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | THERAPEUTIC TESTING IN MURINE MODELS OF FUNGAL INFECTIONS | 75N93024D00029USAspending | $386,096 | Aug 10, 2026 | Jul 27, 2026 – Jan 26, 2028 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RESEARCH ASSISTANCE SERVICES MVP | — | $488,362 | Jul 9, 2026 | Feb 13, 2023 – Feb 12, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | THERAPEUTICS TESTING IN MURINE MODELS OF FUNGAL INFECTIONS TASK ORDER A86 BASE AWARD MULTIPLE CANS | HHSN272201700039IUSAspending | $591,658 | May 18, 2026 | Jul 14, 2017 – May 31, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | RISK UNDERLYING RURAL AREAS LONGITUDINAL (RURAL) HEART AND LUNG STUDY, TASK AREA A - CORE STUDY OPERATIONS (BASE YEAR: 4/22/2026 - 4/21/2027) | 75N98026D00018USAspending | $4,247,461 | Apr 22, 2026 | Apr 22, 2026 – Apr 21, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | RISK UNDERLYING RURAL AREAS LONGITUDINAL (RURAL) HEART AND LUNG STUDY, TASK AREA B.2 - PROTOCOL DEVELOPMENT AND EXAM CONDUCT FOR LIMITED EXAMINATION (EXAM 2): 4/22/2026 - 4/21/2027 | 75N98026D00018USAspending | $3,567,105 | Apr 22, 2026 | Apr 22, 2026 – Apr 21, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | RISK UNDERLYING RURAL AREAS LONGITUDINAL (RURAL) HEART AND LUNG STUDY, TASK AREA B.1 - COMPLETION OF BASELINE EXAMINATION (EXAM 1): 4/22/2026 - 12/31/2026 | 75N98026D00018USAspending | $1,595,622 | Apr 22, 2026 | Apr 22, 2026 – Dec 31, 2026 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | SPECIALIZED PATHOLOGY LAB REFERENCE TESTING | 36C25722D0041USAspending | $707,492 | Jan 29, 2026 | Mar 30, 2026 – Mar 29, 2027 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RESEARCH SUPPORT SERVICES | VA24017D0107USAspending | $391,177 | Sep 12, 2025 | Sep 30, 2019 – Sep 29, 2020 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | RESEARCH SUPPORT SERVICES IGF::OT::IGF | VA24017D0107USAspending | $723,630 | Sep 12, 2025 | Sep 30, 2018 – Sep 30, 2019 |
| Prime | Department of Health and Human Services National Institutes of Health | PRE-CLINICAL MODELS OF INFECTIOUS DISEASE | HHSN272201700039IUSAspending | $340,810 | Mar 19, 2025 | May 1, 2024 – Apr 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | BASE AWARD MULTIPLE CANS TOTAL $656,570.00 | HHSN272201700039IUSAspending | $693,374 | Feb 12, 2025 | Mar 4, 2022 – Aug 31, 2024 |
| Prime | Department of Veterans Affairs Department of Veterans Affairs | INSTITUTIONAL REVIEW BOARDS FOR SOUTH TEXAS VA | — | $790,000 | Sep 4, 2024 | May 15, 2019 – Sep 30, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | TO AWARD TASK ORDER HHSN27200004(A20), "THERAPEUTIC TESTING IN MURINE MODELS OF FUNGAL INFECTIONS - COCCIDIOIDOMYCOSIS" IN THE AMOUNT OF $372,404. | HHSN272201700039IUSAspending | $789,168 | Mar 20, 2024 | Aug 1, 2018 – Jul 24, 2020 |
| Prime | Department of Health and Human Services National Institutes of Health | TO ISSUE TASK ORDER A01, "THERAPEUTICS TESTING IN MURINE MODELS OF FUNGAL INFECTIONS,CANDIDA AURIS, SCEDOSPORIUM SP.,IN THE AMOUNT OF $200,594 | HHSN272201700039IUSAspending | $844,300 | Jul 7, 2023 | Dec 1, 2017 – Feb 11, 2020 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
7 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | THIS SUBAWARD IS TO SUPPORT THE MATIC-2 CLINICAL TRIAL, WHICH EXAMINES THE EFFECTIVENESS, SAFETY AND MECHANISMS BETWEEN MULTIPLE RESUSCITATION PRACTICES IN CHILDREN WITH LIFE THREATENING BLEEDING FROM TRAUMATIC INJURY. AWD00008169-23 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $346,240 | Sep 8, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | THE UTHSC-SA TEAM WILL PROVIDE INPUT TO REQUIREMENTS, SYSTEM DESIGN AND TESTING APPROACH WITH PARTICULAR EMPHASIS ON TRANSLATION OF THE PROTOTYPE SYSTEM INTO A SYSTEM THAT CAN BE USED TO CONDUCT THE CLINICAL STUDY. 2160-S003 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: MA Parent award description: CLINICAL VERIFICATION AND VALIDATION OF A WEARABLE NEAR-INFRARED BLOOD ALCOHOL CONTENT MONITOR. View parent award on USAspending | — | $290,331 | Sep 16, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THE MATIC-2 TRIAL IS A BAYESIAN, RANDOMIZED, MULTICENTER, ADAPTIVE PLATFORM PHASE III TRIAL. THE TRIAL WILL INCLUDE INJURED CHILDREN WITH HEMORRHAGIC SHOCK ANTICIPATED TO REQUIRE MASSIVE BLOOD TRANSFUSION, WHO WILL BE
RANDOMIZED TO RECEIVE EITHER LTOWB OR CT AND TRANEXAMIC ACID OR PLACEBO.
WE HYPOTHESIZE THAT THE USE OF LTOWB IS NON-INFERIOR AND/OR SUPERIOR FOR 24-HOUR MORTALITY AND THAT LTOWB
DOES NOT INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO CT.
WE ALSO HYPOTHESIZE THAT THE USE OF TXA IS SUPERIOR FOR 24-HOUR MORTALITY AND DOES NOT INCREASE THE RISK OF
ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO PLACEBO.
THE PRIMARY OBJECTIVES ARE TO
1. DETERMINE THE EFFECTIVENESS OF LTOWB TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO CT IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE.
2. DETERMINE THE EFFECTIVENESS OF TXA TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO PLACEBO IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE. AWD00008169-23 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Apr 15, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THE MATIC-2 TRIAL IS A BAYESIAN, RANDOMIZED, MULTICENTER, ADAPTIVE PLATFORM PHASE III TRIAL. THE TRIAL WILL INCLUDE INJURED CHILDREN WITH HEMORRHAGIC SHOCK ANTICIPATED TO REQUIRE MASSIVE BLOOD TRANSFUSION, WHO WILL BE
RANDOMIZED TO RECEIVE EITHER LTOWB OR CT AND TRANEXAMIC ACID OR PLACEBO.
WE HYPOTHESIZE THAT THE USE OF LTOWB IS NON-INFERIOR AND/OR SUPERIOR FOR 24-HOUR MORTALITY AND THAT LTOWB
DOES NOT INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO CT.
WE ALSO HYPOTHESIZE THAT THE USE OF TXA IS SUPERIOR FOR 24-HOUR MORTALITY AND DOES NOT INCREASE THE RISK OF
ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO PLACEBO.
THE PRIMARY OBJECTIVES ARE TO
1. DETERMINE THE EFFECTIVENESS OF LTOWB TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO CT IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE.
2. DETERMINE THE EFFECTIVENESS OF TXA TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO PLACEBO IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE. AWD00008169-23 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Apr 15, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THE MATIC-2 TRIAL IS A BAYESIAN, RANDOMIZED, MULTICENTER, ADAPTIVE PLATFORM PHASE III TRIAL. THE TRIAL WILL INCLUDE INJURED CHILDREN WITH HEMORRHAGIC SHOCK ANTICIPATED TO REQUIRE MASSIVE BLOOD TRANSFUSION, WHO WILL BE
RANDOMIZED TO RECEIVE EITHER LTOWB OR CT AND TRANEXAMIC ACID OR PLACEBO.
WE HYPOTHESIZE THAT THE USE OF LTOWB IS NON-INFERIOR AND/OR SUPERIOR FOR 24-HOUR MORTALITY AND THAT LTOWB
DOES NOT INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO CT.
WE ALSO HYPOTHESIZE THAT THE USE OF TXA IS SUPERIOR FOR 24-HOUR MORTALITY AND DOES NOT INCREASE THE RISK OF
ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO PLACEBO.
THE PRIMARY OBJECTIVES ARE TO
1. DETERMINE THE EFFECTIVENESS OF LTOWB TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO CT IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE.
2. DETERMINE THE EFFECTIVENESS OF TXA TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO PLACEBO IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE. AWD00008169-23 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Apr 15, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | THE MATIC-2 TRIAL IS A BAYESIAN, RANDOMIZED, MULTICENTER, ADAPTIVE PLATFORM PHASE III TRIAL. THE TRIAL WILL INCLUDE INJURED CHILDREN WITH HEMORRHAGIC SHOCK ANTICIPATED TO REQUIRE MASSIVE BLOOD TRANSFUSION, WHO WILL BE
RANDOMIZED TO RECEIVE EITHER LTOWB OR CT AND TRANEXAMIC ACID OR PLACEBO.
WE HYPOTHESIZE THAT THE USE OF LTOWB IS NON-INFERIOR AND/OR SUPERIOR FOR 24-HOUR MORTALITY AND THAT LTOWB
DOES NOT INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO CT.
WE ALSO HYPOTHESIZE THAT THE USE OF TXA IS SUPERIOR FOR 24-HOUR MORTALITY AND DOES NOT INCREASE THE RISK OF
ADVERSE EVENTS OR OUTCOMES, SUCH AS THROMBOTIC EVENTS, COMPARED TO PLACEBO.
THE PRIMARY OBJECTIVES ARE TO
1. DETERMINE THE EFFECTIVENESS OF LTOWB TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO CT IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE.
2. DETERMINE THE EFFECTIVENESS OF TXA TO REDUCE ALL-CAUSE 24-HOUR MORTALITY COMPARED TO PLACEBO IN
CHILDREN WITH TRAUMATIC LIFE-THREATENING HEMORRHAGE. AWD00008169-23 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Apr 15, 2024 | — – — |
| Subcontractor | Department of Defense | YEAR6INCLUDINGTIMELINE(MONTHS)
COMPLY WITH ONGOING REGULATORY AND CONTRACTUAL REQUIREMENTS:
X COORDINATE WITH SITES FOR MONTHLY/ANNUAL REPORTS TO SPONSOR (MONTHS 61 €€Œ 72);
X SUBMIT AMENDMENTS, ADVERSE EVENTS, AND PROTOCOL DEVIATIONS (AS NEEDED);
X COORDINATE WITH SITES FOR ANNUAL IRB CONTINUING REVIEW (MONTHS 61 €€Œ 72).
DATA EXTRACTION
X EXTRACT PSYCHOTHERAPY ENCOUNTER NOTE DATA FOR ANALYSIS (MONTHS 61 €€Œ 72) ROS0029-02 Parent award context Parent award agency: Department of Defense · Department of the Army Parent award NAICS: 541720 Parent award performance state: CA Parent award description: IGF::OT::IGF IMPLEMENTATION SCIENCE -PTSD View parent award on USAspending | — | $1,248,441 | Apr 6, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Veterans AffairsGov-sourced
- Department of Health and Human ServicesGov-sourced